======= C19orf53 =======
== Gene Information ==
* **Official Symbol**: C19orf53
* **Official Name**: chromosome 19 open reading frame 53
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=28974|28974]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q9UNZ5|Q9UNZ5]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=C19orf53&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20C19orf53|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/620685|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: May have a potential role in hypercalcemia of malignancy. {ECO:0000250}.
|DUF2462|
|nucleolus|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp492|iCRT14 30μM R08 exp492]]|-2.07|
|[[:results:exp441|GSK-J4 1.5μM R08 exp441]]|-1.76|
|[[:results:exp10|CCCP 0.1μM R00 exp10]]|1.72|
|[[:results:exp415|Trichostatin-A 0.06μM R07 exp415]]|1.72|
|[[:results:exp299|Talazoparib 0.006μM R06 exp299]]|1.73|
|[[:results:exp236|GSK2606414 1μM R05 exp236]]|1.75|
|[[:results:exp423|Zebularine 20μM R07 exp423]]|1.75|
|[[:results:exp219|A-395N 10μM R05 exp219]]|1.78|
|[[:results:exp300|VE-822 0.04μM R06 exp300]]|1.79|
|[[:results:exp12|Chloramphenicol 2μM R00 exp12]]|1.8|
|[[:results:exp123|GSK-LSD1 10μM R03 exp123]]|1.83|
|[[:results:exp501|Methotrexate 0.01μM R08 exp501]]|1.84|
|[[:results:exp434|Vemurafenib 6.6μM R08 exp434]]|1.87|
|[[:results:exp471|Cholesterol 0.003 to 0.006 to 0.1μM on day2 then day6 R08 exp471]]|1.88|
|[[:results:exp229|Dimethyloxaloylglycine 100μM R05 exp229]]|1.92|
|[[:results:exp23|Nocodazole 0.02μM R00 exp23]]|1.94|
|[[:results:exp14|Cycloheximide 0.02μM R00 exp14]]|1.97|
|[[:results:exp71|KU-0063794 3.8μM R02 exp71]]|1.98|
|[[:results:exp409|THZ531 0.11μM R07 exp409]]|1.98|
|[[:results:exp291|LLY-284 2.6μM R06 exp291]]|2|
|[[:results:exp234|Ethanol 0.01 R05 exp234]]|2.03|
|[[:results:exp13|Chloramphenicol 20μM R00 exp13]]|2.04|
|[[:results:exp530|Thioridazine 5μM R08 exp530]]|2.04|
|[[:results:exp1|5-Fluorouracil 2μM R00 exp1]]|2.15|
|[[:results:exp393|Resminostat 0.5μM R07 exp393]]|2.16|
|[[:results:exp16|DABN 2μM R00 exp16]]|2.26|
|[[:results:exp412|THZ531 0.11 to 0.125 to 0.35μM on day4 then day6 R07 exp412]]|2.29|
|[[:results:exp413|THZ531 0.11 to 0.175μM on day4 R07 exp413]]|2.64|
|[[:results:exp29|Rapamycin 1μM R00 exp29]]|2.73|
|[[:results:exp444|THZ531 0.225μM R08 exp444]]|3.56|
^Gene^Correlation^
|[[:human genes:m:mga|MGA]]|0.467|
|[[:human genes:r:rpl18|RPL18]]|0.465|
|[[:human genes:r:rpl35|RPL35]]|0.453|
|[[:human genes:a:adrm1|ADRM1]]|0.444|
|[[:human genes:r:rpl27|RPL27]]|0.437|
|[[:human genes:m:mrto4|MRTO4]]|0.435|
|[[:human genes:o:otub1|OTUB1]]|0.431|
|[[:human genes:r:rps27a|RPS27A]]|0.43|
|[[:human genes:r:rpl32|RPL32]]|0.427|
|[[:human genes:z:zfand5|ZFAND5]]|0.424|
|[[:human genes:r:rpl38|RPL38]]|0.422|
|[[:human genes:s:smg7|SMG7]]|0.422|
|[[:human genes:r:rps16|RPS16]]|0.42|
|[[:human genes:d:ddx56|DDX56]]|0.419|
|[[:human genes:r:rpl18a|RPL18A]]|0.418|
|[[:human genes:h:hgc6.3|HGC6.3]]|0.416|
|[[:human genes:r:rpl17|RPL17]]|0.413|
|[[:human genes:n:narfl|NARFL]]|0.41|
|[[:human genes:e:ebna1bp2|EBNA1BP2]]|0.409|
|[[:human genes:r:rpl14|RPL14]]|0.409|
|[[:human genes:n:nip7|NIP7]]|0.407|
|[[:human genes:r:rpl7|RPL7]]|0.403|
Global Fraction of Cell Lines Where Essential: 175/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|1/1|
|bile duct|10/28|
|blood|2/28|
|bone|6/26|
|breast|8/33|
|central nervous system|17/56|
|cervix|0/4|
|colorectal|2/17|
|esophagus|2/13|
|fibroblast|1/1|
|gastric|1/16|
|kidney|11/21|
|liver|4/20|
|lung|17/75|
|lymphocyte|2/16|
|ovary|9/26|
|pancreas|4/24|
|peripheral nervous system|4/16|
|plasma cell|1/15|
|prostate|0/1|
|skin|6/24|
|soft tissue|1/9|
|thyroid|1/2|
|upper aerodigestive|10/22|
|urinary tract|5/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 1099
* **Expression level (log2 read counts)**: 4.9
{{:chemogenomics:nalm6 dist.png?nolink |}}